Voyageur Pharmaceuticals Ltd. (TSE:VM) has released an update.
Voyageur Pharmaceuticals Ltd., a developer of pharmaceutical ingredients and imaging contrast agents, has filed its annual financial statements and granted 3.7 million stock options to its executives, with the goal of becoming a key player in the imaging market. The company, which owns the Frances Creek barium project and has interests in high-grade iodine and battery mineral projects, is committed to sustainability and aims to achieve carbon neutrality in its manufacturing processes.
For further insights into TSE:VM stock, check out TipRanks’ Stock Analysis page.
